stocktrademan
9 years ago
$AMRI recent news/filings
bullish 20.07
moving aveerage support
## source: finance.yahoo.com
Tue, 24 Nov 2015 16:23:00 GMT ~ Smart Money Is Losing Confidence In Community Trust Bancorp, Inc. (CTBI)
read full: http://www.insidermonkey.com/blog/smart-money-is-losing-confidence-in-community-trust-bancorp-inc-ctbi-387804/
*********************************************************
Tue, 17 Nov 2015 18:04:27 GMT ~ ALBANY MOLECULAR RESEARCH INC Financials
read full: http://finance.yahoo.com/q/is?s=amri
*********************************************************
Fri, 13 Nov 2015 13:00:00 GMT ~ AMRI CEO to Present at Jefferies Autumn 2015 Global Healthcare Conference London
[PR Newswire] - ALBANY, N.Y., Nov. 13, 2015 /PRNewswire/ -- Albany Molecular Research Inc. (NASDAQ: AMRI) announced today that William S. Marth, AMRI's President and Chief Executive Officer, will present at the Jefferies ...
read full: http://finance.yahoo.com/news/amri-ceo-present-jefferies-autumn-130000443.html
*********************************************************
Mon, 09 Nov 2015 20:19:57 GMT ~ ALBANY MOLECULAR RESEARCH INC Files SEC form 10-Q, Quarterly Report
read full: http://biz.yahoo.com/e/151109/amri10-q.html
*********************************************************
Fri, 06 Nov 2015 02:21:38 GMT ~ Edited Transcript of AMRI earnings conference call or presentation 5-Nov-15 1:30pm GMT
read full: http://finance.yahoo.com/news/edited-transcript-amri-earnings-conference-022138910.html
*********************************************************
$AMRI charts
basic chart ## source: stockcharts.com
basic chart ## source: stockscores.com
big daily chart ## source: stockcharts.com
big weekly chart ## source: stockcharts.com
$AMRI company information
## source: otcmarkets.com
Link: http://www.otcmarkets.com/stock/AMRI/company-info
Ticker: $AMRI
OTC Market Place: Not Available
CIK code: 0001065087
Company name: Albany Molecular Research, Inc.
Incorporated In: DE, USA
$AMRI share structure
## source: otcmarkets.com
Market Value: $712,520,644 a/o Dec 04, 2015
Shares Outstanding: 35,501,776 a/o Oct 30, 2015
Float: Not Available
Authorized Shares: Not Available
Par Value: 0.01
$AMRI extra dd links
Company name: Albany Molecular Research, Inc.
## STOCK DETAILS ##
After Hours Quote (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/after-hours
Option Chain (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/option-chain
Historical Prices (yahoo.com): http://finance.yahoo.com/q/hp?s=AMRI+Historical+Prices
Company Profile (yahoo.com): http://finance.yahoo.com/q/pr?s=AMRI+Profile
Industry (yahoo.com): http://finance.yahoo.com/q/in?s=AMRI+Industry
## COMPANY NEWS ##
Market Stream (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stream
Latest news (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/news - http://finance.yahoo.com/q/h?s=AMRI+Headlines
## STOCK ANALYSIS ##
Analyst Research (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/analyst-research
Guru Analysis (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/guru-analysis
Stock Report (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stock-report
Competitors (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/competitors
Stock Consultant (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stock-consultant
Stock Comparison (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/stock-comparison
Investopedia (investopedia.com): http://www.investopedia.com/markets/stocks/AMRI/?wa=0
Research Reports (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/research
Basic Tech. Analysis (yahoo.com): http://finance.yahoo.com/q/ta?s=AMRI+Basic+Tech.+Analysis
Barchart (barchart.com): http://www.barchart.com/quotes/stocks/AMRI
DTCC (dtcc.com): http://search2.dtcc.com/?q=Albany+Molecular+Research%2C+Inc.&x=10&y=8&sp_p=all&sp_f=ISO-8859-1
Spoke company information (spoke.com): http://www.spoke.com/search?utf8=%E2%9C%93&q=Albany+Molecular+Research%2C+Inc.
Corporation WIKI (corporationwiki.com): http://www.corporationwiki.com/search/results?term=Albany+Molecular+Research%2C+Inc.&x=0&y=0
## FUNDAMENTALS ##
Call Transcripts (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/call-transcripts
Annual Report (companyspotlight.com): http://www.companyspotlight.com/library/companies/keyword/AMRI
Income Statement (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/financials?query=income-statement
Revenue/EPS (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/revenue-eps
SEC Filings (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/sec-filings
Edgar filings (sec.gov): http://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001065087&owner=exclude&count=40
Latest filings (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/filings
Latest financials (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/financials
Short Interest (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/short-interest
Dividend History (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/dividend-history
RegSho (regsho.com): http://www.regsho.com/tools/symbol_stats.php?sym=AMRI&search=search
OTC Short Report (otcshortreport.com): http://otcshortreport.com/index.php?index=AMRI
Short Sales (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/short-sales
Key Statistics (yahoo.com): http://finance.yahoo.com/q/ks?s=AMRI+Key+Statistics
Insider Roster (yahoo.com): http://finance.yahoo.com/q/ir?s=AMRI+Insider+Roster
Income Statement (yahoo.com): http://finance.yahoo.com/q/is?s=AMRI
Balance Sheet (yahoo.com): http://finance.yahoo.com/q/bs?s=AMRI
Cash Flow (yahoo.com): http://finance.yahoo.com/q/cf?s=AMRI+Cash+Flow&annual
## HOLDINGS ##
Major holdings (cnbc.com): http://data.cnbc.com/quotes/AMRI/tab/8.1
Insider transactions (yahoo.com): http://finance.yahoo.com/q/it?s=AMRI+Insider+Transactions
Insider transactions (secform4.com): http://www.secform4.com/insider-trading/AMRI.htm
Insider transactions (insidercrow.com): http://www.insidercow.com/history/company.jsp?company=AMRI
Ownership Summary (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/ownership-summary
Institutional Holdings (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/institutional-holdings
Insiders (SEC Form 4) (nasdaq.com): http://www.nasdaq.com/symbol/AMRI/insider-trades
Insider Disclosure (otcmarkets.com): http://www.otcmarkets.com/stock/AMRI/insider-transactions
## SOCIAL MEDIA AND OTHER VARIOUS SOURCES ##
PST (pennystocktweets.com): http://www.pennystocktweets.com/stocks/profile/AMRI
Market Watch (marketwatch.com): http://www.marketwatch.com/investing/stock/AMRI
Bloomberg (bloomberg.com): http://www.bloomberg.com/quote/AMRI:US
Morningstar (morningstar.com): http://quotes.morningstar.com/stock/s?t=AMRI
Bussinessweek (businessweek.com): http://investing.businessweek.com/research/stocks/snapshot/snapshot_article.asp?ticker=AMRI
$AMRI DD Notes ~ http://www.ddnotesmaker.com/AMRI
surf1944
12 years ago
AMRI Further Expands Discovery Capabilities in India
Two Strategic Hires Bring Additional Flexibility to Global Drug Discovery Operations
PR NewswirePress Release: AMRI – Tue, Jun 19, 2012 8:00 AM EDT
ALBANY, N.Y., June 19, 2012 /PRNewswire/ -- As part of a long-term strategic plan to further AMRI's discovery capabilities in India, AMRI (AMRI), a leading global contract research and manufacturing organization, announced the hiring of two experts in medicinal and computational chemistry at its research center located in Hyderabad, India (HRC). Simultaneously, the company announced the completion of the relocation of custom library synthesis resources and capabilities to HRC from the Company's Budapest, Hungary operations. The new hires and relocation of resources provide additional flexibility to enhance productivity and client service for AMRI's global drug discovery operations, which draw upon a broad spectrum of service capabilities from multiple sites.
(Logo: http://photos.prnewswire.com/prnh/20120229/NY61160LOGO)
Srinivas Nanduri, Ph.D., was hired as Director of Medicinal Chemistry in India, reporting to Subramanyam Maddala, President of India Operations. In addition, Suneel Kumar Bommisetty, Ph.D., was hired as Senior Research Associate of Computational Chemistry, reporting to Dr. Nanduri. These newly created positions will further strengthen AMRI's capabilities in problem-solving medicinal chemistry and complement its current strength in custom synthesis at HRC.
"Dr. Nanduri and Dr. Bommisetty bring a high level of medicinal chemistry expertise, a strong track record of industry experience and additional drug discovery project management experience to the Hyderabad site," Mr. Maddala said. "AMRI is committed to providing best-of-class services to our customers, and servicing the entire value chain of contract research services. These additions enhance our capabilities to move towards that target."
In his most recent role as Research Director at Aurigene, Dr. Nanduri was responsible for the execution and overall supervision of multiple integrated drug discovery projects – from hit generation through lead optimization. Prior to that, he was a Chief Scientific Manager at Biocon-BMS Research Centre, where he led projects in the therapeutic areas of oncology, obesity and central nervous system disorders. Dr. Nanduri also had worked at Dr. Reddy's, where he led multiple medicinal chemistry projects in oncology and metabolic disorders, as well as a number of natural products projects in the area of anti-cancer therapy. Dr. Nanduri earned a Ph.D. in Organic Chemistry from Sri Sathya Sai Institute in Andhra Pradesh, India.
Dr. Bommisetty joins AMRI from GVK Biosciences Pvt. Ltd. and brings more than eight years of computational chemistry experience to HRC. He began his career as a Research Associate in 2004 while he obtained his Ph.D. in Computational Chemistry from JNTU. He played a dual role in GVK as a Scientific Associate and also as a senior faculty in GVK Bio campus, leading theory classes and lab sessions on Molecular Modeling, Homology Modeling, Structure-based Drug Design and Analogue-based Drug Design.
Bruce J. Sargent, Ph.D., Senior Vice President of Drug Discovery, commented, "At AMRI we continue to expand our world-class team of scientists to ensure our customers have access to the most experienced and technically adept experts to address their increasingly complex challenges. With the addition of Dr. Nanduri and Dr. Bommisetty, AMRI expands its global medicinal and computational chemistry capabilities in India, complementing the existing capabilities in the U.S. and Singapore. Strengthening our HRC capabilities is an essential element of our SMARTSOURCING™ strategy, which brings together the right mix of AMRI global services, capabilities and translational expertise, while maintaining the same high standards for performance, quality and productivity."
mlkrborn
12 years ago
AMRI short summary of recent history:
InPlay: Albany Molecular announces development and manufacturing deal with Biota Holdings - Yahoo, 1:17:00 AM
AMRI Announces Development and Manufacturing Deal with Biota Holdings Limited - PR Newswire, 1:00:00 AM
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Entry into a Material Definitive Agreement, Termination of a Materi - Yahoo, 4/12/2012 9:47:00 AM
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and - Yahoo, 4/5/2012 9:30:00 AM
InPlay: Albany Molecular signs exclusive option to license its tubulin inhibitor program for cancer - Yahoo, 4/3/2012 1:03:00 AM
AMRI Signs Exclusive Option to License its Tubulin Inhibitor Program for Cancer - PR Newswire, 4/3/2012 1:00:00 AM
AMRI CFO to Present at 11th Annual Needham Healthcare Conference - PR Newswire, 3/28/2012 1:00:00 AM
AMRI Hires Senior Manager to Oversee Facilities at Burlington Aseptic Fill Operations - PR Newswire, 3/27/2012 1:00:00 AM
ALBANY MOLECULAR RESEARCH INC Financials - Yahoo, 3/22/2012 6:04:00 AM
UPDATE 1-Albany Molecular to close Hungary unit, cut 100 jobs - Reuters, 3/21/2012 10:27:00 AM
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Costs Associated with Exit or Disposal Activities - Yahoo, 3/21/2012 10:02:00 AM
ALBANY MOLECULAR RESEARCH INC Files SEC form 10-K, Annual Report - Yahoo, 3/15/2012 9:20:00 AM
0
AMRI Expands Quality Control Leadership to Support Future Growth - PR Newswire, 2/29/2012
5 Biotech Stocks Undervalued By EPS Trends - Seeking Alpha, 2/12/2012 7:21:00 PM
New Star Analyst Rankings for Albany Molecular Research, Inc. - , 2/8/2012 1:31:00 AM
DIARY-U.S. MEETINGS/WEEK AHEAD - Reuters, 2/8/2012 12:25:00 AM
ALBANY MOLECULAR RESEARCH INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements - Yahoo, 2/7/2012 9:03:00 AM
-
AMRI reports net loss of $32M in 2011 - Business Journals, 2/7/2012 4:08:00 AM
AMRI Announces Fourth Quarter and Full Year 2011 Results - PR Newswire, 2/7/2012
surf1944
13 years ago
AMRI Presents Final Phase I Clinical Studies Results of Obesity Compound at the 29th Annual Scientific Meeting of the Obesity Society
Press Release Source: Albany Molecular Research, Inc. On Monday October 3, 2011, 8:00 am EDT
ALBANY, N.Y.--(BUSINESS WIRE)-- AMRI (NASDAQ:AMRI - News) announced today the final results from its Phase I clinical studies on its novel MCH1 receptor antagonist, ALB-127158(a) during the 29th Annual Scientific Meeting of the Obesity Society in Orlando, Fla. Nicholas Moore, Ph.D., director of development and pharmacology at AMRI, reported results from a second Phase I study showing cerebrospinal fluid (CSF) drug levels were achieved with a single 400 mg oral dose of ALB-127158(a). The finding is significant in that it indicates brain/CNS penetration and suggests the compound will reach the drug target receptor in the brain.
Dr. Moore also reiterated previously reported results from a placebo-controlled study which evaluated the safety, tolerability, and efficacy of ALB-127158(a). The study, comprising the single ascending dose (SAD) and 14-day multiple ascending dose (MAD) arms, included standard safety assessments, ECG monitoring, and PK measurements. ALB-127158(a) was well tolerated in both the SAD and the MAD. Reported events were mild and showed little dose relationship. One of the most common events reported in both the SAD and the MAD was loss of appetite. Reductions in “hunger,” “desire to eat,” and test meal consumption were observed. The study met both its primary and secondary objectives, demonstrating safety and tolerability.
Analysis of the CSF and other data suggested a higher than predicted dose would be required for chronic treatment. Therefore, AMRI has decided not to progress ALB-127158(a) further.
“Although we have decided not to progress ALB-127158(a) toward Phase II clinical studies, we have multiple follow-on compounds that we believe may show better potential for partnering and clinical development,” said Bruce Sargent, Ph.D., senior vice president of drug discovery.
surf1944
13 years ago
AMRI awarded NIH contract worth as much as $43M
The Business Review - by Barbara Pinckney
Date: Friday, August 19, 2011, 11:07am EDT
AMRI has been awarded an NIH grant worth as much as $43 million.
Richard A. D'Errico | The Business Review
AMRI has been awarded an NIH grant worth as much as $43 million.
Albany Molecular Research Inc. has been awarded a National Institutes of Health contract that could be worth up to $43 million over five years.
The Albany, N.Y.-based company will provide chemistry and other drug discovery technologies to support efforts by the National Institute of Neurological Disorders and Stroke (NINDS), an arm of the NIH, to develop pre-clincal drug candidates to treat diseases of the central nervous system.
AMRI has been collaborating with NINDS since 2005 on novel treatments for spinal muscular atrophy, a degenerative neuromuscular disease. The company now will provide its chemistry services to neuroscientists throughout the country with the goal of developing pre-clinical drug candidates suitable for advanced development and ultimately clinical trials in humans.
The company will receive initial funding of up to $10 million for the first phase of the project, expected to begin this month, with the objective of delivering at least one Phase I clinical trial candidate. It could receive up to $43 million based on the number of approved projects and availability of funds over five years.
Thomas D’Ambra, chairman, president and CEO of AMRI, said the company was chosen after a “highly competitive, rigorous application process.”
“We are pleased to support NIH/NINDS’ efforts and provide our discovery resources to the neuroscience research community and to patients who suffer from devastating neurological and degenerative diseases, such as macular degeneration and Alzheimer’s disease,” added Dr. D’Ambra. ...
analogdog
17 years ago
AMRI Announces Third Quarter Results; Continues Double-Digit Growth in Contract Revenue and EPS
Albany, NY (November 6, 2007) — AMRI (NASDAQ: AMRI) today announced results for the third quarter ended September 30, 2007. For the quarter, the company reported growth in total contract revenue and net income. Growth was driven by continued strong performance in the company’s Development/Small Scale business component.
Highlights for the quarter include:
* An increase in total revenue, including 10% growth in contract revenue
* Double-digit year-over-year contract revenue growth in Development/Small Scale business segments
* Operating income increased 173%, from $0.8 million in Q3 2006 to $2.1 million in Q3 2007
* Net income of $2.0 million, a 41% increase year-over-year
* Year-over-year improvement in contract services gross margin
* The opening of a new R&D facility in Hyderabad, India
* A four-year research collaboration with the Cystic Fibrosis Foundation worth up to $23.7 million, aimed at identifying novel treatments that address the core defect in cystic fibrosis
* The hiring of Steve Jennings, a 30-year veteran of both the pharmaceutical and medical device industries, to lead AMRI’s global sales and business development efforts.
Third Quarter Results
Total revenue for the third quarter of 2007 was $47.6 million, an increase of 8% compared to total revenue of $44.2 million in the third quarter of 2006.
Total contract revenue in the third quarter of 2007 was $41.6 million, an increase of 10% compared to total contract revenue of $37.9 million in the third quarter of 2006. Total contract revenue encompasses revenue from AMRI’s Discovery Services, Development/Small Scale Manufacturing, and Large Scale Manufacturing business components.
* Development/Small Scale Manufacturing - contract revenue for the third quarter was $13.1 million, an increase of 37% compared to $9.6 million in the third quarter of 2006. The increase results from continued strong demand for pharmaceutical development services.
* Discovery Services - contract revenue for the third quarter of 2007 was $10.5 million, an increase of 5% from $10 million in the third quarter of 2006.
* Large Scale Manufacturing - contract revenue for the third quarter of 2007 was $17.9 million, a decrease of 2% compared to $18.2 million in the third quarter of 2006.
Recurring royalties from Allegra® in the third quarter of 2007 were $6.0 million, a decrease of 6% compared to recurring royalties of $6.3 million in 2006. AMRI earns royalties from worldwide sales of the non-sedating antihistamine Allegra® (Telfast® outside the United States), as well as the authorized generic, for patents relating to the active ingredient in Allegra.
Net income in the third quarter of 2007 was $2.0 million, or $0.06 per diluted share, compared to net income of $1.4 million, or $0.04 per diluted share, in the third quarter of 2006.
Year-to-Date
Total revenue for the first nine-months of 2007 was $145.3 million, an increase of 9% compared to total revenue of $133.2 million during the same period in 2006.
Total contract and milestone revenue for the first nine-months of 2007 was $124.3 million, an increase of 11% compared to total contract and milestone revenue of $112.5 million during the comparable period in 2006.
Total contract revenue for the first nine-months of 2007 was $122.7 million, an increase of 9% compared to total contract revenue of $112.5 million in 2006.
* Development/Small Scale Manufacturing - contract revenue for the nine-month period ended September 30, 2007 was $34.0 million, an increase of 27% from $26.8 million in 2006.
* Discovery Services - contract revenue was $30.1 million, an increase of 10% from $27.3 million in 2006.
* Large Scale Manufacturing - contract revenue was $58.6 million, an increase of 1% compared to $58.2 million in the nine-month period ended September 30, 2006.
Milestone revenue for the first nine-months of 2007 was $1.6 million. Milestone revenue includes $1.5 million recorded in the second quarter of 2007, which resulted from the company’s 2005 licensing agreement with Bristol-Myers Squibb.
Recurring royalties from Allegra® for the first nine-months of 2007 were $21.0 million, an increase of 1% compared to royalty revenue of $20.7 million in 2006.
Net income under U.S. generally accepted accounting principles (U.S. GAAP) for the nine-month period ended September 30, 2007 was $9.8 million, or $0.30 per diluted share, compared to net income of $2.9 million, or $0.09 per diluted share, for the comparable period in 2006. Excluding Large Scale Manufacturing restructuring charges of $185,000 (net of taxes) recorded in the first and second quarters of 2007, net income for the nine months ended September 30, 2007 on an adjusted basis was $10.0 million, or $0.31 per diluted share. Excluding the charge recorded in the second quarter of 2006 to reduce the carrying value of the former Mount Prospect Research Center, net income for the nine-months ended September 30, 2006 on an adjusted basis was $5.2 million, or $0.16 per diluted share. For a reconciliation of net income and earnings per diluted share as reported to adjusted net income and earnings per diluted share, please see Table 1 at the end of this press release.
AMRI Chairman, President and CEO Thomas E. D'Ambra said, “Contract revenue for the third quarter grew 10% from last year and was on the high end of our contract revenue projections. Noteworthy, during the third quarter we saw continued revenue growth in our Discovery Services and Development/Small Scale business components. Our development/small scale component in particular remained very strong, with a 37% year-over-year quarterly increase and a 27% year-to-date increase. On the Discovery Services side, several natural products collaborations helped drive revenue growth, particularly at our U.S.-based operations. As we ramp up our international operations and begin to fully realize the benefits of our flexible cost model, we have high expectations for continued long-term growth in worldwide Discovery Services. In Large Scale Manufacturing we continue to remain on track in our overall efforts to improve the product mix and, more importantly, our margins. Our recently announced purchase of large scale manufacturing facilities in India (now referred to as AMRI India) is expected to be accretive to earnings in 2008.”
D'Ambra continued, “we continue to be bullish about the near- and long-term potential of our natural products collections. Within the past year we have initiated natural products-based research collaborations with four different customers. Many of these collaborations offer AMRI the opportunity to receive upfront payments, funded research and downstream revenue potential. AMRI’s investment in these resources and complementary technologies is beginning to deliver and impact our bottom line.”
Liquidity and Capital Resources
At September 30, 2007, AMRI had cash, cash equivalents and investments of $105.9 million, compared to $110.9 million at June 30, 2007. The decrease of $5 million in cash, cash equivalents and investments in the third quarter of 2007 was due primarily to purchases of property, plant and equipment of $4.6 million, and principal payments on the company's outstanding debt of $1.0 million. These items were partially offset by cash flow from operations of $0.6 million. Cash flow from operations increased by $0.6 million in the third quarter of 2007 as compared to the third quarter of 2006. Total debt at September 30, 2007 was $15.1 million, compared to $18.5 million at December 31, 2006. Cash, cash equivalents and investments, net of debt, were $90.8 million at September 30, 2007. Total common shares outstanding, net of treasury shares, at September 30, 2007 were 32,945,555.
Contract & Milestone Revenue Guidance
AMRI Chief Financial Officer Mark T. Frost provided contract revenue guidance for the fourth quarter, as well as contract and milestone revenue guidance for the full year 2007. “In the fourth quarter, we expect contract revenue to range from $43 million to $45 million, an increase of up to 11% from the fourth quarter of 2006,” he said. “For the full year 2007, we estimate contract and milestone revenue to range of $167 to $169 million, an increase of up to 11% from 2006.”
Third Quarter Conference Call
The company will hold a conference call at 10:00 a.m. Eastern Time on November 6, 2007 to discuss its quarterly results, business highlights and prospects. During the conference call, the company may discuss information not previously disclosed to the public. Individuals interested in listening to the conference call should dial 866-550-6338 (for domestic calls) or 347-284-6930 (for international calls) at 9:45 a.m. and use passcode 4648533. Replays of the call will be available for seven days following the call beginning at 12:00 p.m. on November 6, 2007. To access the replay by telephone, please call 888-203-1112 (for domestic calls) or 719-457-0820 (for international calls) and use access code 4648533. In addition, replays of the call will be available for twelve months on the company's website at www.amriglobal.com/investor/investcc.html.